There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Elevance Health (ELV – Research Report), Agilon Health (AGL – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
Elevance Health (ELV)
In a report released today, Kevin Fischbeck from Bank of America Securities maintained a Buy rating on Elevance Health. The company’s shares closed last Monday at $545.87, close to its 52-week high of $547.99.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elevance Health with a $604.45 average price target.
See today’s best-performing stocks on TipRanks >>
Agilon Health (AGL)
In a report released today, Adam Ron from Bank of America Securities maintained a Buy rating on Agilon Health. The company’s shares closed last Monday at $5.47, close to its 52-week low of $4.41.
According to TipRanks.com, Ron is a 4-star analyst with an average return of
Currently, the analyst consensus on Agilon Health is a Moderate Buy with an average price target of $6.60, implying a 22.0% upside from current levels. In a report issued on May 7, RBC Capital also maintained a Buy rating on the stock with a $8.00 price target.
Boston Scientific (BSX)
In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific. The company’s shares closed last Monday at $75.46.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $80.84, representing an 8.1% upside. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELV:
- Elevance Health price target raised to $585 from $575 at Mizuho
- Elevance Health price target raised to $600 from $580 at Truist
- Elevance Health price target raised to $575 from $574 at RBC Capital
- Elevance Health price target raised to $600 from $557 at Wells Fargo
- Elevance Health price target raised to $605 from $585 at UBS
